Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study.

J Cancer · 2019 · PMC6856567 · PMID 31762802

Europe PMC DOI

hedged sentence

0.0450

closest p · 0.9× alpha

0.0450

boldest claim

The sentences

marginally significantp= 0.045actually significant

Marginally significant was the difference in PFS (11 vs 10.3 months; HR: 0.78; 95% CI, 0.61 to 0.99; p= 0.045).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.